Drug consumption and additional risk factors associated with microscopic colitis: Case-control study

Revista Espanola de Enfermedades Digestivas

Volumn 107, Issue 6, 2015, Pages 347-353

  Guagnozzi, Danila ^a   Lucendo, Alfredo J ^a   Angueira, Teresa ^a   González Castillo, Sonia ^a   Tenias, José María ^b  

^a HOSPITAL GENERAL DE TOMELLOSO   (Spain)

^b HOSPITAL GENERAL LA MANCHA CENTRO   (Spain)

Author keywords

Chronic diarrhoea; Drug intake; Irritable bowel syndrome; Microscopic colitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; HYPNOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; FRUCTOSE; NEUROPROTECTIVE AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE CONTROL STUDY; CELIAC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGENOUS COLITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FECES ANALYSIS; FEMALE; HUMAN; IRRITABLE COLON; LYMPHOCYTE; LYMPHOCYTIC COLITIS; MALE; MICROSCOPIC COLITIS; PROSPECTIVE STUDY; RISK FACTOR; WEIGHT REDUCTION; AGED; ANALOGS AND DERIVATIVES; AUTOIMMUNE DISEASE; CHEMICALLY INDUCED; COLITIS, MICROSCOPIC; COMPLICATION; MIDDLE AGED; STATISTICAL MODEL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; COLITIS, MICROSCOPIC; FEMALE; FRUCTOSE; HUMANS; IRRITABLE BOWEL SYNDROME; LOGISTIC MODELS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84945279930     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Jawhari A, Talbot JC. Microscopic, lymphocytic and collagenous colitis. Histopathology 1996;29:101-10.
2. Pardi DS, Kelly CP. Microscopic colitis. Gastroenterology 2011; 140:1155-65.
3. Guagnozzi D, Lucendo AJ. Advances in knowledge on microscopic colitis: From bench to bedside. Rev Esp Enferm Dig 2015;107:98-108.
4. Zins BJ, Sandborn WJ, Tremaine WJ. Collagenous and lymphocytic colitis: Subject review and therapeutic alternatives. Am J Gastroenterol 1995;90:1394-400.
5. Fernandez-Bañares F, Salas A, Esteve M, et al. Collagenous and lymphocytic colitis: Evaluation of clinical and histological features, response to treatment and long-term follow-up. Am J Gastroenterol 2003;98:340-7.
6. Geboes K, Villanacci V. Terminology for the diagnosis of colitis. J Clin Pathol 2005;58:1133-4.
7. Münch A, Aust D, Boohr J, et al; European Microscopic Colitis Group (EMCG). Microscopic colitis: Current status, present and future challenges. J Crohn's Colitis 2012;6:932-45.
8. Tong J, Zheng Q, Zhang C, et al. Incidence, prevalence and temporal trends of microscopic colitis: A systematic review and meta-analysis. Am J Gastroenterol 2015;110:165-76.
9. Olesen M, Eriksson S, Bohr J, et al. Microscopic colitis: A common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut 2004;53:346-50.
10. Bohr J, Tysk C, Eriksson S, et al. Collagenous colitis in Orebro, Sweden, an epidemiological study 1984-1993. Gut 1995;37:394-7.
11. Fernandez-Bañares F, Salas A, Forné M, et al. Incidence of collagenous and lymphocytic colitis: A 5-years population-based study. Am J Gastroenterol 1999;94:418-23.
12. Agnarsdottir M, Gunnlaugsson O, Orvar KB, et al. Collagenous and lymphocytic colitis in Iceland. Dig Dis Sci 2002;47:1122-8.
13. Pardi DS, Loftus EV Jr, Smyrk TC, et al. The epidemiology of microscopic colitis: A population based study in Olmsted Country, Minnesota. Gut 2007;56:504-8.
14. Williams JJ, Kaplan GG, Makhija S, et al. Microscopic colitis defining incidence rates and risk factors: A population-based study. Clin Gastroenterol Hepatol 2008;6:35-40.
15. Fernandez-Bañares F, Salas A, Esteve M, et al. Evolution of the incidence of collagenous colitis and lymphocytic colitis in Terrassa, Spain: A population-based study. Inflamm Bowel Dis 2011;17:1015-20.
16. Guagnozzi D, Lucendo AJ, Angueira-Lapeña T. Prevalence and incidence of microscopic colitis in patients with diarrhoea of unknown aetiology in a region in central Spain. Dig Liver Dis 2012;44:384-8.
17. Keszthelyi D, Jansen SV, Schouten GA, et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: A casecontrol study. Aliment Pharmacol Ther 2010;32:1124-8.
18. Fernandez-Bañares F, Esteve M, Espinós JC, et al. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol 2007;102:324-30.
19. Fernandez-Bañares F, Sousa MR, Salas A, et al; RECOMINA Project, GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa). Impact of current smoking on the clinical course of microscopic colitis. Inflamm Bowel Dis 2013;19:1470-6.
20. Riddell RH, Tanaka M, Mazzoleni G. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: A case-control study. Gut 1992;33:683-6.
21. Pascua MF, Kedia P, Weiner MG, et al. Microscopic colitis and medication use. Clin Med Insights Gastroenterol 2010;3:11-9.
22. Beaugerie L, Patey N, Brousse N. Ranitidine, diarrhoea, and lymphocytic colitis. Gut 1995;37:708-11.
23. Piche T, Raimondi V, Schneider S, et al. Acarbose and lymphocytic colitis. Lancet 2000;356:1246.
24. Beaugerie L, Luboinski J, Brousse N, et al. Drug induced lymphocytic colitis. Gut 1994;35:426-8.
25. Wilcox GM, Mattia A. Collagenous colitis associated with lansoprazole. J Clin Gastroenterol 2002;34:164-6.
26. Wilcox GM, Mattia AR. Microscopic colitis associated with omeprazole and esomeprazole exposure. J Clin Gastroenterol 2009;43:551-3.
27. Chassany O, Michaux A, Bergmann JF. Drug-induced diarrhoea. Drug Saf 2000;22:53-72.
28. Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013;7:827-51.
29. Marsh MN. Gluten major histocompatibility complex, and the small intestine. A molecular and immunological approach to the spectrum of gluten sensity ("celiac sprue"). Gastroenterology 1992;102:330-54.
30. Corazza GR, Villanacci V. Coeliac disease. J Clin Pathol 2005;58:573-4.
31. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-9.
32. Bohr J, Tysk C, Yang P, et al. Autoantibodies and immunoglobulins in collagenous colitis. Gut 1996;39:73-6.
33. Maroy B. Acute lymphocytic colitis due to carbamazepine. Gastroenterol Clin Biol 2010;34:155-6.
34. Alvarez-Pérez P, Rubio-Nazabal E, Marey-López J, et al. Colitis linfocitaria inducida por carbamacepina. An Med Interna 2004;21:572-3.
35. Olesen M, Eriksson S, Bohr J, et al. Lymphocytic colitis: A retrospective clinical study of 199 Swedish patients. Gut 2004;53:536-41.
36. Bohr J, Tysk C, Eriksson S, et al. Collagenous colitis: A retrospective study of clinical presentation and treatment in 163 patients. Gut 1996;39:846-51.
37. Gremse DA, Boudreaux CW, Manci EA. Collagenous colitis in children. Gastroenterology 1993;104:906-9.
38. Mahajan L, Wyllie R, Goldblum J. Lymphocytic colitis in a paediatric patients: A possible adverse reaction to carbamazepine. Am J Gastroenterol 1997;92:2126-7.
39. Faresjo A, Grodzinsky E, Johansson S, et al. Self-reported use of pharmaceuticals among patients with irritable bowel syndrome in primary care. J Manag Care Pharm 2008;14:870-7.
40. Nyhlin N, Bohr J, Eriksson S, et al. Systematic review: Microscopic colitis. Aliment Pharmacol Ther 2006;23:1525-34.
41. Vigren L, Sjoberg K, Benoni C, et al. Is smoking a risk factor for collagenous colitis? Scand J Gastroenterol 2011;46:1334-9.
42. Nyhlin N, Montgomery SM, Wickbom A, et al. Symptom burden in collagenous and lymphocytic colitis compared to a matched control group. Gut 2009;58(Supl. II):A309.
43. Yen EF, Pokhrel B, Du H, et al. Current and past cigarette smoking significantly increase risk for microscopic colitis. Inflamm Bowel Dis 2012;18:1835-41.